Teckro today announced five significant appointments to its leadership team. The hires follow Teckro’s Series C funding announcement in February, featuring investment from major US venture capital firms. To date, Teckro has raised $43 million.

Jean-Paul Kress, Picture: Quantum Genomics

Germany-based MorphoSys AG announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer. The appointment will take effect on September 1, 2019.

Jim Allison.

Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already served as part-time co-Chairman since the company’s inception in 2017.

Jim Allison.

Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma from the MD Anderson Cancer Center to join the company as Company Strategic Advisors

Alex C. Sapir. Picture: Dova Pharmaceuticals

ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), today announced that Alex C. Sapir has been appointed Chief Executive Officer (CEO) and elected to the Board of Directors, effective June 10, 2019. Mr. Sapir succeeds Dr. Eddy Littler, who will serve as Chief Operating Officer (COO).

Paul Hudson. Picture: Sanofi

At its meeting on June 6th of 2019, Sanofi’s Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to retire.

Dr. Dietmar Berger. Picture: Sanofi

Sanofi has a new head of development, which the company confirmed on Wednesday with a short tweet: "Dietmar Berger, MD, PhD, joins #Sanofi as Head of Development, overseeing our clinical portfolio across all therapeutic areas and helping us bring transformative new medicines to patients."

Thpmas Blomquist. Picture: Biotage

Tomas Blomquist has been appointed as the new CEO and President of Biotage AB.

Picture: Dr Martin treder

Dr. Martin Treder has informed Affimed that he intends to step down from his position as Chief Scientific Officer to pursue new opportunities.

Mark Hammond. Picture: PBD Biotech

Novel diagnostic developer PBD Biotech announces the appointment of new CEO Mark Hammond to drive the company’s expansion.